Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.58 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.57 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.57 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.57 |
| ▸ | FAP | Q12884 | 6/20 | 0.57 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | AKT2 | P31751 | 1/20 | 0.53 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.53 |
| ▸ | FPR1 | P21462 | 4/20 | 0.51 |
| ▸ | FPR2 | P25090 | 4/20 | 0.51 |
| ▸ | GRB2 | P62993 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5151499 | 1.00 | DPP4 (0.58) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL5230718 | 0.92 | DPP4 (0.66) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL5229026 | 0.92 | DPP4 (0.66) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL10615090 | 0.91 | DPP4 (0.65) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL8390334 | 0.91 | DPP4 (0.65) | DPP4DPP7DPP8DPP9FAP | |
| Hydrochloric Acid SCHEMBL8647667 | 0.91 | DPP4 (0.65) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL7305245 | 0.91 | DPP4 (0.65) | DPP4DPP7DPP8DPP9FAP | |
| Hydrochloric Acid SCHEMBL10615092 | 0.90 | DPP4 (0.63) | DPP4DPP7DPP8DPP9FAP | |
| Hydrochloric Acid SCHEMBL8993841 | 0.90 | DPP4 (0.63) | DPP4DPP7DPP8DPP9FAP | |
| Trifluoroacetic Acid SCHEMBL6824509 | 0.85 | HDAC8 (0.58) | DPP4DPP7DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157454-B2 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2007-01-02 | — | — | US | disclosed |
| US-20040116353-A1 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | SANOFI (FR) | 2004-06-17 | — | — | US | disclosed |
| US-6610882-B2 | Affinity for bradykinin receptors; antithrombotics | SANOFI-SYNTHELABO (FR) | 2003-08-26 | — | — | US | disclosed |
| US-20030073641-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2003-04-17 | — | — | US | disclosed |
| US-20020115685-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2002-08-22 | — | — | US | disclosed |
| US-6433185-B1 | ANTIINFLAMMATORY AGENTS; ANALGESICS | SANOFI-SYNTHELABO (FR) | 2002-08-13 | — | — | US | disclosed |
| US-6313120-B1 | TREATMENT OR PREVENTION OF DISEASES INVOLVING BRADYKININ RECEPTORS | SANOFI-SYNTHELABO (FR) | 2001-11-06 | — | — | US | disclosed |
| EP-0877737-B1 | NOVEL N-(ARYLSULPHONYL)AMINO ACID DERIVATIVES HAVING BRADYKININ RECEPTOR AFFINITY | SANOFI SYNTHELABO (FR) | 2001-08-01 | — | — | EP | disclosed |
| US-6100278-A | COMPOUNDS HAVING AFFINITY FOR BRADYKININ RECEPTORS; ANTIINFLAMMATORY AGENTS | SANOFI-SYNTHELABO (FR) | 2000-08-08 | — | — | US | disclosed |
| US-6015812-A | N-(arylsulphonyl)amino acid derivatives having bradykinin receptor affinity | SANOFI-SYNTHELABO (FR) | 2000-01-18 | — | — | US | disclosed |
| EP-0877737-A1 | NOVEL N-(ARYLSULPHONYL)AMINO ACID DERIVATIVES HAVING BRADYKININ RECEPTOR AFFINITY | SANOFI (FR) | 1998-11-18 | — | — | EP | disclosed |
| WO-1997025315-A1 | NOVEL N-(ARYLSULPHONYL)AMINO ACID DERIVATIVES HAVING BRADYKININ RECEPTOR AFFINITY | SANOFI (FR) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115685-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | CYP2C9, ADRM1, ADRA1D | DPP4 1159/4885DPP7 716/4885DPP8 1651/4885 |
| US-20030073641-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | CYP2C9, ADRM1, ADRA1D | DPP4 1159/4885DPP7 716/4885DPP8 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.